These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16026115)

  • 1. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications.
    Aukrust P; Gullestad L; Ueland T; Damås JK; Yndestad A
    Ann Med; 2005; 37(2):74-85. PubMed ID: 16026115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of anticytokine therapy in congestive heart failure.
    Aukrust P; Yndestad A; Damås JK; Gullestad L
    Am J Cardiovasc Drugs; 2004; 4(3):169-77. PubMed ID: 15134469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches.
    Gullestad L; Aukrust P
    Am J Cardiol; 2005 Jun; 95(11A):17C-23C; discussion 38C-40C. PubMed ID: 15925560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.
    Aukrust P; Yndestad A; Damås JK; Gullestad L
    Autoimmun Rev; 2004 Mar; 3(3):221-7. PubMed ID: 15110235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory cytokines in heart failure: mediators and markers.
    Gullestad L; Ueland T; Vinge LE; Finsen A; Yndestad A; Aukrust P
    Cardiology; 2012; 122(1):23-35. PubMed ID: 22699305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulating therapy: new treatment modality in congestive heart failure.
    Aukrust P; Damås JK; Gullestad L
    Congest Heart Fail; 2003; 9(2):64-9. PubMed ID: 12671336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets.
    Gullestad L; Aukrust P
    Heart Fail Monit; 2001; 2(1):8-13. PubMed ID: 12634893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents targeting inflammation in heart failure.
    Gullestad L; Kjekshus J; Damås JK; Ueland T; Yndestad A; Aukrust P
    Expert Opin Investig Drugs; 2005 May; 14(5):557-66. PubMed ID: 15926863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of intravenous immunoglobulin in the treatment of chronic heart failure.
    Aukrust P; Yndestad A; Ueland T; Damås JK; Frøland SS; Gullestad L
    Int J Cardiol; 2006 Sep; 112(1):40-5. PubMed ID: 16893578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune modulation therapy in heart failure.
    Mielniczuk LM; Baughman KL
    Congest Heart Fail; 2006; 12(2):91-6; quiz 97-8. PubMed ID: 16596043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential mechanisms of benefit with thalidomide in chronic heart failure.
    Aukrust P; Yndestad A; Damås JK; Ueland T; Øie E; Gullestad L
    Am J Cardiovasc Drugs; 2007; 7(2):127-34. PubMed ID: 17503883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic inflammation in heart failure--the whys and wherefores.
    Yndestad A; Damås JK; Oie E; Ueland T; Gullestad L; Aukrust P
    Heart Fail Rev; 2006 Mar; 11(1):83-92. PubMed ID: 16819581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure.
    Hanna A; Frangogiannis NG
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):849-863. PubMed ID: 32902739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory trials in chronic heart failure.
    Aukrust P; Yndestad A; Ueland T; Damås JK; Gullestad L
    Heart Fail Monit; 2006; 5(1):2-9. PubMed ID: 16547529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of inflammation in the progression of heart failure.
    Yndestad A; Damås JK; Øie E; Ueland T; Gullestad L; Aukrust P
    Curr Cardiol Rep; 2007 May; 9(3):236-41. PubMed ID: 17470337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design.
    Torre-Amione G; Bourge RC; Colucci WS; Greenberg B; Pratt C; Rouleau JL; Sestier F; Moyé LA; Geddes JA; Nemet AJ; Young JB;
    Can J Cardiol; 2007 Apr; 23(5):369-76. PubMed ID: 17440642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats.
    Wang J; Li C; Cao Y; Wang Q; Lu L; Chang H; Wu Y; Han J; Wang W; Tu P; Wang Y
    BMC Complement Altern Med; 2015 Oct; 15():352. PubMed ID: 26445960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Heart Failure and Inflammation: What Do We Really Know?
    Dick SA; Epelman S
    Circ Res; 2016 Jun; 119(1):159-76. PubMed ID: 27340274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
    Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure: novel therapeutic approaches.
    Patel C; Deoghare S
    J Postgrad Med; 2015; 61(2):101-8. PubMed ID: 25766342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.